UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
October 29, 2015
Date of Report (Date of Earliest
Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-31187 | 870638336 |
| (State or other jurisdiction of | (Commission File | (IRS Employer Identification |
| incorporation) | Number) | No.) |
| 6425 Abrams, Ville St- Laurent, Quebec, Canada | H4S 1X9 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (514) 331-7440
Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx to Report Third Quarter 2015 Financial Results on November 3, 2015.
| Exhibit | Description |
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES CORP.
| Dated: October 29, 2015 | By: /s/ Andre Godin |
| ------------------- | |
| Andre Godin | |
| Vice President and Chief Financial Officer |
IntelGenx to Report Third Quarter 2015 Financial Results on November 3, 2015
Saint Laurent, Quebec – October 29, 2015 - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx"), a leading drug delivery company focused on the development of innovative products based on its proprietary oral drug delivery technologies, today announced that it will release its third quarter 2015 results for the period ended September 30, 2015, on November 3, 2015 at the close of the financial markets.
An accompanying conference call will take place the following day and will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Wednesday, November 4, 2015
Time: 9:00 a.m. EST
Conference dial-in: 1-866-393-4306
Conference ID: 66937976
International dial-in: (734) 385-2616
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.
CONTACT:
Edward Miller, Director, Investor
Relations
IntelGenx Corp.
T: +1 514-331-7440 (ext. 217)
edward@intelgenx.com